Russia struggling with adequate access to hepatitis C drugs
A number of leading patient organizations in Russia have called on the national government to increase procurements of drugs against hepatitis C, according to recent statements by representatives of associations and some local media, reports The Pharma Letter’s local correspondent.
In recent years, the fight against hepatitis C has become one of the priorities for the Russian government, which is part of its efforts for the reduction of mortality rate and increase the average life expectancy in the country up to 78 years.
According to preliminary estimates in a study by the Ministry of Finance's Research Institute, the overall value of investments to treat all currently identified patients with hepatitis C (while maintaining the current cost of drugs) is estimated at 606 billion roubles ($8.45 billion)
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze